ZA978512B - Olanzapine dihydrate D. - Google Patents

Olanzapine dihydrate D.

Info

Publication number: ZA978512B
Authority: ZA; South Africa
Prior art keywords: olanzapine dihydrate; olanzapine; dihydrate
Prior art date: 1996-09-23

Application number

ZA978512A

Other languages

English (en)

Inventor

Samuel Dean Larsen

Susan Marie Reutzel

John Richard Nicols

Gregory Alan Stephenson

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-09-23

Filing date

1997-09-22

Publication date

1999-03-23

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21832112&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA978512(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-09-22 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

1999-03-23 Publication of ZA978512B publication Critical patent/ZA978512B/xx

Links

FUOBHGGXKJHKDF-UHFFFAOYSA-N 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine dihydrate Chemical compound O.O.C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 FUOBHGGXKJHKDF-UHFFFAOYSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/38—[b, e]- or [b, f]-condensed with six-membered rings

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Neurology (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

ZA978512A 1996-09-23 1997-09-22 Olanzapine dihydrate D. ZA978512B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US2648696P	1996-09-23	1996-09-23

Publications (1)

Publication Number	Publication Date
ZA978512B true ZA978512B (en)	1999-03-23

Family

ID=21832112

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA978512A ZA978512B (en)	1996-09-23	1997-09-22	Olanzapine dihydrate D.

Country Status (34)

Country	Link
US (1)	US6251895B1 (fr)
EP (1)	EP0831097B1 (fr)
JP (1)	JP2001500878A (fr)
KR (1)	KR100516088B1 (fr)
CN (1)	CN1146567C (fr)
AR (1)	AR009801A1 (fr)
AT (1)	ATE221074T1 (fr)
AU (1)	AU720366B2 (fr)
BR (1)	BR9711541A (fr)
CA (1)	CA2266444C (fr)
CO (1)	CO4900057A1 (fr)
CZ (1)	CZ299247B6 (fr)
DE (1)	DE69714165T2 (fr)
DK (1)	DK0831097T3 (fr)
EA (1)	EA001881B1 (fr)
EG (1)	EG23815A (fr)
ES (1)	ES2180899T3 (fr)
HU (1)	HU226167B1 (fr)
ID (1)	ID21924A (fr)
IL (1)	IL128956A0 (fr)
MY (1)	MY125467A (fr)
NO (1)	NO323979B1 (fr)
NZ (1)	NZ334346A (fr)
PE (1)	PE110298A1 (fr)
PL (1)	PL194074B1 (fr)
PT (1)	PT831097E (fr)
RS (1)	RS49597B (fr)
SI (1)	SI0831097T1 (fr)
SV (1)	SV1997000079A (fr)
TR (1)	TR199900639T2 (fr)
TW (1)	TW518335B (fr)
UA (1)	UA56184C2 (fr)
WO (1)	WO1998011893A1 (fr)
ZA (1)	ZA978512B (fr)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA978515B (en) *	1996-09-23	1999-03-23	Lilly Co Eli	Intermediates and process for preparing olanzapine
US6617321B2 (en)	1997-09-30	2003-09-09	Eli Lilly And Company	2-methyl-thieno-benzodiazepine formulation
DE69917663T2 (de) *	1998-09-30	2005-05-25	Eli Lilly And Co., Indianapolis	2-methyl-thieno-benzodiazepin-formulierung
WO2001047933A1 (fr) *	1999-12-28	2001-07-05	Cipla Limited	Nouvelles formes polymorphes d'olanzapine
US7022698B2 (en)	1999-12-28	2006-04-04	U & I Pharmaceuticals, Ltd.	Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof
EP1313742A1 (fr) *	2000-08-31	2003-05-28	Dr. Reddy's Laboratories Ltd.	Procede de preparation d'hydrates d'olanzapine et de conversion de ceux-ci en formes cristallines d'olanzapine
US6740753B2 (en)	2001-01-04	2004-05-25	Geneva Pharmaceuticals, Inc.	Olanzapine crystal modification
CA2464306A1 (fr) *	2001-10-29	2003-05-08	Dr. Reddy's Laboratories Ltd.	Dihydrate-ii d'olanzapine: son procede de preparation et son utilisation
SI1513846T1 (sl) *	2002-05-31	2011-11-30	Sandoz Ag	Postopek za pripravo olanzapina form I
SI21270A (sl)	2002-07-15	2004-02-29	Krka, Tovarna Zdravil, D.D., Novo Mesto	Kristalne oblike olanzapina in postopki za njihovo pripravo
US7407955B2 (en)	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7323459B2 (en) *	2002-12-24	2008-01-29	Teva Pharmaceutical Industries Ltd.	Crystal forms, methods for their preparation and method for preparation of olanzapine
US6861422B2 (en)	2003-02-26	2005-03-01	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
EP1684734A2 (fr) *	2003-11-18	2006-08-02	3M Innovative Properties Company	Compositions d'administration medicamenteuse transdermique renfermant de l'olanzapine
ATE504588T1 (de)	2004-01-27	2011-04-15	Synthon Bv	Stabile salze von olanzapin
DE102004029784A1 (de)	2004-06-21	2006-01-05	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004030502A1 (de)	2004-06-24	2006-01-12	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
DE102004033670A1 (de)	2004-07-09	2006-02-02	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
ES2289974T1 (es) *	2004-07-14	2008-02-16	Shasun Chemicals And Drugs Limited	Metodo mejorado para producir la forma i de la olanzapina.
US20060074088A1 (en)	2004-08-14	2006-04-06	Boehringer Ingelheim International Gmbh	Dihydropteridinones for the treatment of cancer diseases
US7759485B2 (en)	2004-08-14	2010-07-20	Boehringer Ingelheim International Gmbh	Process for the manufacture of dihydropteridinones
US20060058311A1 (en)	2004-08-14	2006-03-16	Boehringer Ingelheim International Gmbh	Combinations for the treatment of diseases involving cell proliferation
US20060035903A1 (en)	2004-08-14	2006-02-16	Boehringer Ingelheim International Gmbh	Storage stable perfusion solution for dihydropteridinones
US7728134B2 (en)	2004-08-14	2010-06-01	Boehringer Ingelheim International Gmbh	Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
EP1630163A1 (fr)	2004-08-25	2006-03-01	Boehringer Ingelheim Pharma GmbH & Co.KG	Dihydropteridinones, procédés de préparation et leur utilisation en tant que médicaments
WO2006027800A1 (fr) *	2004-09-06	2006-03-16	Shasun Chemicals And Drugs Limited	Nouveau procede pour la preparation de forme i polymorphe d'olanzapine de purete pharmaceutique
WO2006034797A1 (fr)	2004-09-29	2006-04-06	Bayer Healthcare Ag	Forme thermodynamiquement stable de tosylate de bay 43-9006
DE102004054054A1 (de)	2004-11-05	2006-05-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
AU2005307797B2 (en) *	2004-11-16	2011-06-02	Alkermes Pharma Ireland Limited	Injectable nanoparticulate olanzapine formulations
DE102004058337A1 (de)	2004-12-02	2006-06-14	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
EP1838716B1 (fr)	2005-01-05	2011-06-01	Eli Lilly And Company	Dihydrate d'olanzapine pamoate
DE102005035891A1 (de)	2005-07-30	2007-02-08	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
WO2007067714A2 (fr) *	2005-12-08	2007-06-14	The Mclean Hospital Corporation	Traitement de séquelles de troubles psychiatriques
US7834176B2 (en) *	2006-01-26	2010-11-16	Sandoz Ag	Polymorph E of Olanzapine and preparation of anhydrous non-solvated crystalline polymorphic Form I of 2-methyl-4(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] benzodiazepine (Olanzapine Form I) from the polymorphic Olanzapine Form E
US7439358B2 (en)	2006-02-08	2008-10-21	Boehringer Ingelheim International Gmbh	Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
PE20080251A1 (es)	2006-05-04	2008-04-25	Boehringer Ingelheim Int	Usos de inhibidores de dpp iv
EP1852108A1 (fr)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	Compositions d'inhibiteurs de la DPP IV
CN102838599A (zh)	2006-05-04	2012-12-26	贝林格尔.英格海姆国际有限公司	多晶型
AR062927A1 (es)	2006-10-11	2008-12-17	Bayer Healthcare Ag	4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
US7718649B1 (en)	2006-11-10	2010-05-18	Pisgah Labs, Inc.	Physical states of a pharmaceutical drug substance
US8039461B1 (en)	2006-11-10	2011-10-18	Pisgah Laboratories, Inc.	Physical states of a pharmaceutical drug substance
EP3098223A1 (fr)	2007-08-03	2016-11-30	Boehringer Ingelheim International GmbH	Forme cristalline d'un dérivé de dihydroptéridione
PE20091730A1 (es)	2008-04-03	2009-12-10	Boehringer Ingelheim Int	Formulaciones que comprenden un inhibidor de dpp4
US8883863B1 (en)	2008-04-03	2014-11-11	Pisgah Laboratories, Inc.	Safety of psuedoephedrine drug products
CA2724533C (fr) *	2008-07-24	2014-07-29	Handa Pharmaceuticals, Llc	Formulation antipsychotique atypique stabilisee
UY32030A (es)	2008-08-06	2010-03-26	Boehringer Ingelheim Int	"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
KR20200118243A (ko)	2008-08-06	2020-10-14	베링거 인겔하임 인터내셔날 게엠베하	메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
BRPI0919288A2 (pt)	2008-09-10	2015-12-15	Boehring Ingelheim Internat Gmbh	teriapia de combinação para tratamento de diabetes e condições relacionadas.
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EA022310B1 (ru)	2008-12-23	2015-12-30	Бёрингер Ингельхайм Интернациональ Гмбх	Солевые формы органического соединения
AR074990A1 (es)	2009-01-07	2011-03-02	Boehringer Ingelheim Int	Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
NZ599298A (en)	2009-11-27	2014-11-28	Boehringer Ingelheim Int	Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
WO2011138421A1 (fr)	2010-05-05	2011-11-10	Boehringer Ingelheim International Gmbh	Combinaison thérapeutique
NZ603319A (en)	2010-06-24	2015-04-24	Boehringer Ingelheim Int	Diabetes therapy
US8546566B2 (en)	2010-10-12	2013-10-01	Boehringer Ingelheim International Gmbh	Process for manufacturing dihydropteridinones and intermediates thereof
AR083878A1 (es)	2010-11-15	2013-03-27	Boehringer Ingelheim Int	Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
US9358233B2 (en)	2010-11-29	2016-06-07	Boehringer Ingelheim International Gmbh	Method for treating acute myeloid leukemia
US9370535B2 (en)	2011-05-17	2016-06-21	Boehringer Ingelheim International Gmbh	Method for treatment of advanced solid tumors
CA2841552C (fr)	2011-07-15	2020-06-23	Boehringer Ingelheim International Gmbh	Quinazolines substituees, la preparation de celles-ci et l'utilisation de celles-ci dans des compositions pharmaceutiques
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
EP3685839A1 (fr)	2012-05-14	2020-07-29	Boehringer Ingelheim International GmbH	Linagliptin pour son utilisation dans le traitement de l'albuminurie et des maladies liees au rein
US20130303554A1 (en)	2012-05-14	2013-11-14	Boehringer Ingelheim International Gmbh	Use of a dpp-4 inhibitor in sirs and/or sepsis
WO2013174767A1 (fr)	2012-05-24	2013-11-28	Boehringer Ingelheim International Gmbh	Dérivé de xanthine en tant qu'inhibiteur de la dpp-4 à utiliser dans la modification de l'apport alimentaire et dans la régulation des préférences alimentaires
WO2014078568A1 (fr)	2012-11-14	2014-05-22	The Johns Hopkins University	Méthodes et compositions pour le traitement de la schizophrénie
JP2016027003A (ja) *	2012-11-20	2016-02-18	大蔵製薬株式会社	長期間安定なオランザピンの水性医薬製剤
WO2015011236A1 (fr)	2013-07-26	2015-01-29	Boehringer Ingelheim International Gmbh	Traitement du syndrome myélodysplasique
ES2950384T3 (es)	2014-02-28	2023-10-09	Boehringer Ingelheim Int	Uso médico de un inhibidor de DPP-4
US9867831B2 (en)	2014-10-01	2018-01-16	Boehringer Ingelheim International Gmbh	Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
WO2017211979A1 (fr)	2016-06-10	2017-12-14	Boehringer Ingelheim International Gmbh	Combinaisons de linagliptine et de metformine

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5302716A (en) *	1986-01-16	1994-04-12	Schering Corporation	Fused benzazepines
GB9009229D0 (en) *	1990-04-25	1990-06-20	Lilly Industries Ltd	Pharmaceutical compounds
US5229382A (en) *	1990-04-25	1993-07-20	Lilly Industries Limited	2-methyl-thieno-benzodiazepine
AU668159B2 (en) *	1992-05-29	1996-04-26	Lilly Industries Limited	Pharmaceutical compounds
MX9606595A (es)	1994-06-28	1997-05-31	Grace W R & Co	Bolsa que tiene parches protectores.
EG24221A (en) *	1995-03-24	2008-11-10	Lilly Co Eli	Process for preparing olanzapine
IL117612A0 (en) *	1995-03-24	1996-07-23	Lilly Co Eli	Granule formulation for olanzapine
US5631250A (en) *	1995-03-24	1997-05-20	Eli Lilly And Company	Process and solvate of 2-methyl-thieno-benzodiazepine
EG23659A (en) *	1995-03-24	2007-03-26	Lilly Co Eli	Process and crystal forms of methyl-thieno-benzodiazepine

1997
- 1997-09-18 TR TR1999/00639T patent/TR199900639T2/xx unknown
- 1997-09-18 IL IL12895697A patent/IL128956A0/xx not_active IP Right Cessation
- 1997-09-18 CA CA002266444A patent/CA2266444C/fr not_active Expired - Fee Related
- 1997-09-18 WO PCT/US1997/016586 patent/WO1998011893A1/fr not_active Ceased
- 1997-09-18 NZ NZ334346A patent/NZ334346A/en not_active IP Right Cessation
- 1997-09-18 CZ CZ0098999A patent/CZ299247B6/cs not_active IP Right Cessation
- 1997-09-18 HU HU0000065A patent/HU226167B1/hu not_active IP Right Cessation
- 1997-09-18 RS YUP-154/99A patent/RS49597B/sr unknown
- 1997-09-18 BR BR9711541A patent/BR9711541A/pt not_active IP Right Cessation
- 1997-09-18 EA EA199900325A patent/EA001881B1/ru not_active IP Right Cessation
- 1997-09-18 CN CNB971981213A patent/CN1146567C/zh not_active Expired - Fee Related
- 1997-09-18 AU AU44241/97A patent/AU720366B2/en not_active Ceased
- 1997-09-18 ID IDW990059A patent/ID21924A/id unknown
- 1997-09-18 UA UA99031634A patent/UA56184C2/uk unknown
- 1997-09-18 JP JP10514881A patent/JP2001500878A/ja not_active Withdrawn
- 1997-09-18 KR KR10-1999-7002423A patent/KR100516088B1/ko not_active Expired - Fee Related
- 1997-09-18 PL PL97332541A patent/PL194074B1/pl unknown
- 1997-09-22 EP EP97307379A patent/EP0831097B1/fr not_active Expired - Lifetime
- 1997-09-22 DE DE69714165T patent/DE69714165T2/de not_active Expired - Lifetime
- 1997-09-22 SV SV1997000079A patent/SV1997000079A/es active IP Right Grant
- 1997-09-22 PT PT97307379T patent/PT831097E/pt unknown
- 1997-09-22 SI SI9730408T patent/SI0831097T1/xx unknown
- 1997-09-22 ZA ZA978512A patent/ZA978512B/xx unknown
- 1997-09-22 ES ES97307379T patent/ES2180899T3/es not_active Expired - Lifetime
- 1997-09-22 CO CO97055058A patent/CO4900057A1/es unknown
- 1997-09-22 AT AT97307379T patent/ATE221074T1/de active
- 1997-09-22 MY MYPI97004393A patent/MY125467A/en unknown
- 1997-09-22 DK DK97307379T patent/DK0831097T3/da active
- 1997-09-23 PE PE1997000853A patent/PE110298A1/es not_active Application Discontinuation
- 1997-09-23 US US08/935,883 patent/US6251895B1/en not_active Expired - Fee Related
- 1997-09-23 EG EG98597A patent/EG23815A/xx active
- 1997-09-23 AR ARP970104361A patent/AR009801A1/es not_active Application Discontinuation
1998
- 1998-02-27 TW TW086113833A patent/TW518335B/zh not_active IP Right Cessation
1999
- 1999-03-19 NO NO19991339A patent/NO323979B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
HU226167B1 (hu)	2008-05-28
CA2266444C (fr)	2007-01-09
NO323979B1 (no)	2007-07-30
CO4900057A1 (es)	2000-03-27
KR100516088B1 (ko)	2005-09-22
SI0831097T1 (en)	2003-02-28
CZ98999A3 (cs)	1999-08-11
EA199900325A1 (ru)	1999-08-26
CZ299247B6 (cs)	2008-05-28
EP0831097A3 (fr)	1998-04-29
ATE221074T1 (de)	2002-08-15
MY125467A (en)	2006-08-30
DK0831097T3 (da)	2002-09-02
SV1997000079A (es)	1999-01-13
JP2001500878A (ja)	2001-01-23
RS49597B (sr)	2007-06-04
EG23815A (en)	2007-08-19
PL194074B1 (pl)	2007-04-30
NO991339L (no)	1999-03-19
DE69714165T2 (de)	2003-01-23
DE69714165D1 (de)	2002-08-29
AU4424197A (en)	1998-04-14
NZ334346A (en)	2000-05-26
HUP0000065A3 (en)	2000-11-28
YU15499A (sh)	2000-03-21
AU720366B2 (en)	2000-06-01
PE110298A1 (es)	1999-01-18
BR9711541A (pt)	1999-08-24
US6251895B1 (en)	2001-06-26
EP0831097A2 (fr)	1998-03-25
KR20000048519A (ko)	2000-07-25
NO991339D0 (no)	1999-03-19
AR009801A1 (es)	2000-05-03
EP0831097B1 (fr)	2002-07-24
IL128956A0 (en)	2000-02-17
CN1146567C (zh)	2004-04-21
UA56184C2 (uk)	2003-05-15
ES2180899T3 (es)	2003-02-16
CA2266444A1 (fr)	1998-03-26
WO1998011893A1 (fr)	1998-03-26
TR199900639T2 (xx)	1999-06-21
TW518335B (en)	2003-01-21
PT831097E (pt)	2002-10-31
PL332541A1 (en)	1999-09-13
EA001881B1 (ru)	2001-10-22
HK1009809A1 (en)	1999-06-11
ID21924A (id)	1999-08-12
CN1234738A (zh)	1999-11-10
HUP0000065A2 (hu)	2000-06-28

Publication	Publication Date	Title
IL128956A0 (en)	2000-02-17	Olanzapine dihydrate D
ZA979516B (en)	1998-05-12	Thienopyrimidines.
ZA977156B (en)	1998-02-19	Thienopyrimidines.
ZA9710429B (en)	1998-06-10	Broad-spectrumδ-endotoxins.
ZA979199B (en)	1998-05-11	Aminothiophenecarboxamides.
ZA976168B (en)	1998-02-02	3-Ureido-pyridofurans and -pyridothiophenes.
ZA97521B (en)	1997-08-04	19-Nor-pregnene derivatives.
ZA977206B (en)	1999-11-12	Arylalkanoylpyridazines.
ZA978304B (en)	1998-03-24	3-alkyl-3-phenyl-piperidines.
ZA976056B (en)	1998-02-03	Block former.
ZA992443B (en)	1999-10-01	Hydroxy-methyl-hexanones.
ZA978379B (en)	1998-03-24	Synchronizer.
ZA993123B (en)	1999-11-08	Trisresorcinyltriazines.
ZA97572B (en)	1997-08-04	1-pyrazol-3-ylethyl-4-indol-3-ylpiperidines.
ZA974052B (en)	1998-01-14	New benzothiazolinones.
ZA971466B (en)	1997-08-28	Endothelin-receptor-antagonists.
ZA976022B (en)	1998-02-02	Cycloalkano-pyridines.
ZA971167B (en)	1997-08-25	Heterocyclyl-ergoline derivatives.
CY2322B1 (en)	2003-11-14	Benzoaeguequinoline derivatives.
ZA974056B (en)	1998-01-14	New thiazolopyridines.
ZA971474B (en)	1997-08-28	Endothelin-receptor-antagonists.
ZA977142B (en)	1998-02-16	Belt-lock.
ZA975469B (en)	1997-12-22	X14-mannitol.
GB9723445D0 (en)	1998-01-07	Manufacture
ZA9710674B (en)	1998-06-12	4-Cyclohexylphenyl-oxazolines.